Jefferies Maintains Bristol-Myers Squibb Co to Hold with Price Target $57.00

Brokerage firm Jefferies Maintains its rating on Bristol-Myers Squibb Co(NYSE:BMY). In a research note issued to the investors, the brokerage major Lowers the price-target to $57.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Sep 12, 2016.

In a different note, On Sep 9, 2016, Barclays said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Lowers the price-target to $75.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Aug 19, 2016, UBS said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Lowers the price-target to $80.00 per share. The shares have been rated ‘Buy’ by the firm. On Aug 11, 2016, Berenberg said it Downgrades its rating on Bristol-Myers Squibb Co. In the research note, the firm Lowers the price-target to $80.00 per share. The shares have been rated ‘Hold’ by the firm. On Aug 8, 2016, Citigroup said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Lowers the price-target to $80.00 per share. The shares have been rated ‘Buy’ by the firm. On Aug 8, 2016, Jefferies said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Lowers the price-target to $80.00 per share. The shares have been rated ‘Hold’ by the firm. On Aug 8, 2016, Deutsche Bank said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Lowers the price-target to $68.00 per share. The shares have been rated ‘Hold’ by the firm.

Bristol-Myers Squibb Co (BMY) made into the market gainers list on Tuesdays trading session with the shares advancing 0.87% or 0.48 points. Due to strong positive momentum, the stock ended at $55.56, which is also near the day’s high of $56.28. The stock began the session at $55.35 and the volume stood at 99,40,177 shares. The 52-week high of the shares is $77.12 and the 52 week low is $55.02. The company has a current market capitalization of $92,833 M and it has 1,67,08,58,500 shares in outstanding.

Bristol-Myers Squibb Co has also declared a cash dividend of $0.3800 on Aug 3, 2016. The shares will quote ex-dividend on Oct 5, 2016 and the record date has been fixed on Oct 7, 2016. The dividend payable date has been fixed on Nov 1, 2016.

Bristol-Myers Squibb Co(BMY) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $4.87B. Analysts had an estimated revenue of $4.61B. Earnings per share were $0.69. Analysts had estimated an EPS of $0.66.

Several Insider Transactions has been reported to the SEC. On Sep 9, 2016, Lamberto Andreotti (director) sold 21,600 shares at $56.87 per share price.Also, On Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at $72.69 per share price.On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price, according to the Form-4 filing with the securities and exchange commission.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.